published meta-analysis   sensitivity analysis   studies

Comirnaty (tozinameran - Pfizer/BIONTECH) in COVID-19 prophylaxis (children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultsWalter E.B. (Children <12 Years of Age), 2021 0.09 [0.03; 0.32] 0.09[0.03; 0.32]Walter E.B. (Children <12 Years of Age), 202110%2,186NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-06-04 08:36 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 330 - treatments: 758 - roots T: 290